Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04402073
Title	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)
Acronym	PersoMed-I
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	European Organisation for Research and Treatment of Cancer - EORTC
Indications	medulloblastoma medulloblastoma SHH activated and TP53 wild-type medulloblastoma WNT activated
Therapies	Cisplatin + Lomustine + Vincristine Sulfate Cisplatin + Lomustine + Sonidegib + Vincristine Sulfate
Age Groups:	adult \| child \| senior
Covered Countries	NLD \| ITA \| FRA \| ESP \| DEU \| AUT \| AUS